Streetbeat News

PSYBF

PsyBio Therapeutics Corp

Industry

Research and Development in Biotechnology

Open

0.01

Mkt cap

300K

Volume

High

0.01

P/E Ratio

N/A

52-wk high

0.02

Low

0.00

Div yield

N/A

52-wk low

0.00

Massachusetts is moving towards decriminalization of natural substances, with growing interest in the therapeutic potential of psychedelics. PsyBio Therapeutics (OTC:PSYBF) holds a license for synthetic psilocybin developed by Miami University's Andrew Jones, who is now collaborating with the University of Cincinnati on non-hallucinogenic substances.

Portfolio Pulse from Lara Goldstein

June 08, 2023 | 1:44 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.